Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Free Cash Flow (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Free Cash Flow for 17 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 96.67% to $5.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$13.8 million through Dec 2025, up 50.18% year-over-year, with the annual reading at -$13.8 million for FY2025, 50.18% up from the prior year.
  • Free Cash Flow for Q4 2025 was $5.9 million at Myriad Genetics, down from $18.3 million in the prior quarter.
  • The five-year high for Free Cash Flow was $64.7 million in Q1 2021, with the low at -$75.3 million in Q3 2023.
  • Average Free Cash Flow over 5 years is -$15.2 million, with a median of -$8.1 million recorded in 2021.
  • The sharpest move saw Free Cash Flow crashed 838.24% in 2023, then surged 753.57% in 2025.
  • Over 5 years, Free Cash Flow stood at $5.1 million in 2021, then crashed by 243.14% to -$7.3 million in 2022, then tumbled by 786.3% to -$64.7 million in 2023, then skyrocketed by 104.64% to $3.0 million in 2024, then skyrocketed by 96.67% to $5.9 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $5.9 million, $18.3 million, and -$16.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.